Anoma's Gambit: A Nonprofit Play to Save Independent Oncology

NASHVILLE, TN – July 09, 2026 – In an industry defined by relentless consolidation, a new entity has emerged with a maneuver designed to counter the tide. Anoma Cancer Collective (ACC) launched this week, not as another acquirer of independent medical practices, but as a nonprofit foundation armed with a novel financial strategy. Its stated mission: to offer community oncology centers a path to survival that doesn't involve selling out to a corporate or hospital giant.

For decades, the playbook for independent cancer centers has been shrinking. Faced with declining reimbursements, rising operational costs, and the capital-intensive race for new technology, physicians have been forced into what the collective’s own manifesto calls an “unacceptable choice” between independence and survival. ACC is betting it can write a new chapter, using a sophisticated financial structure to preserve the autonomy of local, physician-led cancer care.

A New Playbook Against Consolidation

The prevailing narrative in oncology has been one of absorption. Independent practices, once the backbone of community care, are increasingly becoming integrated assets of sprawling hospital systems. This trend has raised concerns about diminished physician autonomy, reduced patient choice, and the potential for care decisions to be influenced by corporate balance sheets rather than patient needs.

Anoma Cancer Collective enters this high-stakes environment proposing a “third way.” The organization, a 501(c)3 nonprofit, has launched with an initial cohort of eight cancer centers across five states. It provides these partners with capital, shared operational infrastructure, and a national network of expertise. The critical distinction, however, is its promise to do so without taking ownership or stripping the clinical leadership from the physicians who built the practices. It aims to strengthen, not absorb.

“This model gives centers a way to invest in their future and strengthen what they already do well,” said Hejal Patel, MD, Chief Medical Officer of ACC, in a statement. “It allows them to continue to deliver high-quality care without giving up their independence.” This sentiment cuts to the core of the pressure point ACC is looking to relieve: the fear that a financial lifeline must invariably come with strings that bind physicians to a new set of corporate masters.

The Financial Engineering Behind Independence

The engine behind ACC’s ambitious plan is not a new medical device or treatment protocol, but a piece of financial engineering typically reserved for large hospital systems and public works projects: tax-exempt bond financing. This is where the strategy moves from a mission statement to a market-defining maneuver.

Operational support and the model’s architecture come from Radiation Business Solutions (RBS), a firm that has spent years supporting oncology centers. RBS reportedly invested over $10 million and 18 months in developing the ACC framework, signaling a significant commitment. The firm has a track record, having deployed over $300 million in municipal bonds with radiation centers over the last three years, effectively de-risking the concept.

The model was piloted in Alaska with the Aurora Integrated Oncology Foundation (AIOF), which served as the proof-of-concept. By successfully applying bond financing to a nonprofit network of community centers there, RBS and its partners demonstrated the model’s viability. Now, with ACC, they are scaling it nationally.

The structure is backed by a formidable trio of institutional investors: Baird Advisors, Capital Research and Management Company, and new partner First Eagle Investment Management, LLC. The underwriting, managed by Loop Capital Markets, further cements the financial legitimacy of the enterprise. For participating cancer centers, this structure unlocks access to capital for upgrading facilities, investing in next-generation technology like theranostics, and reinforcing staffing—all while providing a financial event for founding physicians who have spent decades building their practices.

The Ripple Effect on Patients and Communities

While the corporate structure is complex, ACC leadership insists the patient-level benefits are straightforward. “For patients and families, the benefit is real and immediate,” said Louis Potters, MD, a radiation oncologist and ACC Board member. By providing capital and infrastructure, the model is designed to keep advanced cancer care within the communities that need it, preventing the all-too-common scenario where patients must travel long distances for specialized treatment.

Beyond clinical access, the nonprofit structure is intended to transform these centers into what ACC calls “engines of generosity.” The model creates a platform for local philanthropy to fund services that fall outside of direct treatment, such as expanded cancer screenings, patient navigation programs, transportation assistance, and survivorship support. This reinvestment in the community’s health ecosystem is a key differentiator from purely for-profit consolidation plays, where revenue is often extracted from the community and redirected to shareholders.

The promise to reduce administrative burden via RBS’s centralized services is another critical component. The goal is to free physicians from the operational minutiae that contribute to burnout, allowing them to refocus on the doctor-patient relationship that drew them to medicine in the first place.

A Calculated Disruption in a High-Stakes Market

Anoma Cancer Collective is not a charity for failing practices; its model targets successful, profitable centers that want a more secure and autonomous future. It is a strategic move to create a resilient, decentralized network capable of competing with the scale of integrated health systems and private equity-backed consolidators.

The launch of ACC is a clear signal that a segment of the market believes there is a viable alternative to the binary choice of acquisition or decline. By aligning the financial incentives of physicians with the long-term needs of patients and communities, the collective is wagering that a mission-driven, professionally managed network can do more than just survive—it can lead. The entire healthcare industry will be watching to see if this sophisticated gambit pays off.